Welcome to our dedicated page for Trinity Biotech Plc news (Ticker: TRIB), a resource for investors and traders seeking the latest updates and insights on Trinity Biotech Plc stock.
Trinity Biotech plc (NASDAQ: TRIB) is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. The TRIB news feed on Stock Titan aggregates company press releases and related coverage so readers can follow developments across its infectious disease, diabetes, oncology and maternal health portfolios.
News items for Trinity Biotech commonly highlight regulatory milestones and product launches. Recent announcements include large orders for its TrinScreen HIV rapid screening test, WHO and in-country regulatory approvals enabling offshored and outsourced manufacturing of TrinScreen HIV and Uni-Gold HIV, and expanded rollout of a high-capacity HbA1c column system for the FDA-cleared Premier Hb9210 analyzer. These updates provide insight into how the company is executing its transformation plan and adjusting its manufacturing footprint.
Investors and observers can also use the TRIB news page to track progress in newer areas such as continuous glucose monitoring, where the company has reported breakthrough clinical trial results for a redesigned CGM sensor and references its CGM+ solution, as well as oncology and maternal health initiatives, including development of the EpiCapture prostate cancer test and the PreClara Ratio preeclampsia biomarker service. Capital structure and governance developments, such as credit agreement amendments with Perceptive Advisors, Nasdaq listing compliance updates, and annual general meeting outcomes, are also disclosed through news and associated SEC filings.
By reviewing the Trinity Biotech news stream, users can see how product approvals, manufacturing changes, financing arrangements and clinical data releases intersect with the company’s stated strategy in diagnostics and diabetes management. This page can be revisited to follow new regulatory clearances, commercial orders, pipeline updates and corporate actions as they are reported by the company.
Trinity Biotech reported Q3 2020 revenues of $32.0 million, showing a 30.2% increase from Q3 2019. Point-of-Care revenues fell 46.8% to $2.1 million, impacted by COVID-19 logistics, while Clinical Laboratory sales rose 44.6% to $29.9 million. Operating profit surged to $9.1 million, a sevenfold increase, due to higher revenues and improved gross margins of 52.4%. The company launched a Covid-19 IgG ELISA antibody test, awaiting FDA approval, and anticipates ongoing strong demand for Covid-related products. Net profit stood at $7.3 million, with earnings per share at 35.0 cents.
Trinity Biotech (Nasdaq: TRIB) will report its third quarter 2020 financial results on November 17, 2020, followed by a conference call at 11:00 am ET. The call can be accessed via toll-free numbers in the US and internationally. A replay will be available until November 24, 2020. The company specializes in diagnostic systems, particularly for detecting infectious diseases and quantifying chemical parameters. Investors are advised that forward-looking statements involve risks, including regulatory impacts and competition.
Trinity Biotech (Nasdaq: TRIB) reported Q2 2020 revenues of $16.0 million, a 28.8% decline from $22.5 million in Q2 2019, primarily due to Covid-19's impact on its business. Point-of-Care revenues fell 41%, while Clinical Laboratory revenues dropped 27.5%. Gross profit increased to $6.9 million, achieving a gross margin of 42.9%. The company implemented cost-saving measures, resulting in a $0.5 million operating profit. Trinity Biotech is actively pursuing Covid-19 testing solutions, having filed for FDA approval for an ELISA antibody test.
Dublin-based Trinity Biotech has submitted an Emergency Use Authorization (EUA) application to the FDA for its Covid-19 IgG ELISA antibody test. This test aims to identify individuals exposed to SARS-CoV-2, showcasing a specificity over 98% and sensitivity exceeding 95%. The company has also developed a rapid antibody test that requires just one drop of blood and can provide results in 12 minutes. Additionally, Trinity Biotech is increasing production of its Viral Transport Media to support ongoing Covid-19 testing demands.
Trinity Biotech (Nasdaq: TRIB) will report its second quarter 2020 financial results on August 25, 2020, accompanied by a conference call at 11:00 AM ET. The call will provide insights into the company’s performance for the quarter, focusing on diagnostic products for both point-of-care and clinical labs. Interested participants can join via US Toll Free or International numbers. A replay will be available until September 1, 2020. The company continues to navigate challenges related to COVID-19 while pursuing growth in diagnostics.
Trinity Biotech plc (Nasdaq: TRIB) announced that its subsidiary, Primus Corporation, received a warning letter from the U.S. FDA following an inspection of its Kansas City facility in January 2020. The letter mainly addresses issues concerning the Ultra2 product range. The company emphasizes its commitment to quality and compliance, expressing confidence in its products and plans to collaborate with the FDA to resolve these issues. A response detailing corrective actions will be submitted within 15 business days.
Trinity Biotech plc (Nasdaq: TRIB) reported Q1 2020 revenues of $21.2 million, down from $22.0 million in Q1 2019. Point-of-Care revenue increased by 4.4% to $3.3 million, while Clinical Laboratory revenue fell 5.3% to $17.8 million. Gross profit was $9.3 million with a margin of 43.8%. Operating profit rose to $1.7 million, and basic EPS increased to 1.7 cents. The company anticipates Q2 revenues of $13-15 million due to impacts from Covid-19, though it is in the validation phase for a Covid-19 IgG test.
Trinity Biotech (Nasdaq: TRIB) will announce its Q1 2020 financial results on May 27, 2020. A conference call is scheduled for the same day at 11:00 AM ET (4:00 PM BST) to discuss the results. Interested parties can join via a designated dial-in number or access a simultaneous webcast. The replay of the call will be available until June 3, 2020. The company specializes in diagnostic products for both point-of-care and clinical laboratory markets, with global operations in over 75 countries.